  Protocol No. 13-101227      
04/06/2018 V 0.16  i Title: HIT HEADS Trial: Head Injury Treatment with Healthy and Advanced Dietary Supplements: A randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAA’s) in the treatment of concussion Short Title BCAA’s in concussion Drug or Device Name(s): Branched chain amino acids FDA IND 117570 eIRB Number 13-010227 Protocol Date:  Amendment 1 Date: 06/13/2014 (Full Amendment)  Amendment 2 Date: 09/18/2014 (Full Amendment) Amendment 3 Date: 03/10/2015 (Full Amendment) Amendment 4 Date: 4/24/2015 (Full Amendment) Amendment 5 Date: 7/9/2015 (Full Amendment) Amendment 6 Date: 8/13/2015 (Full Amendment) Amendment 7 Date: 10/13/2015 (Full Amendment) Amendment 8 Date: 12/21/2015 (Full Amendment) Amendment 9 Date: 03/07/2016 (Full Amendment) Amendment 10 Date: 09/11/2017 (Full Amendment) Amendment 11 Date: 11/20/2017 (Full Amendment) Amendment 12 Date: 12/19/2017 (Full Amendment) Amendment 13 Date: 01/11/2018 (Full Amendment) Amendment 14 Date: 04/06/2018 (Full Amendment) Amendment 15 Date: 09/27/2018 (Full Amendment) Amendment 16 Date: 06/17/2019 (Full Amendment)  
 Funding Agency: Dana Foundation  [ADDRESS_131338], 6th floor [LOCATION_001], NY [ZIP_CODE] 
  Protocol No. 13-101227      
04/06/2018 V 0.16  ii     Principal Investigator  [INVESTIGATOR_117728], MD, MSCE  Department of Emergency Medicine The Children's Hospi[INVESTIGATOR_117729]: ([PHONE_2675] Email: [EMAIL_2349]  Co-Investigator and IND Sponsor Akiva Cohen, PhD The Children’s Hospi[INVESTIGATOR_117730], Room 816-H Philadelphia, PA [ZIP_CODE] Phone [PHONE_2676] Email: [EMAIL_2350]  Co-Investigator  Matthew Kirschen, MD PhD Department of Anesthesia and Critical Care and  Division of Neurology, Department of Pediatrics The Children's Hospi[INVESTIGATOR_117729]: ([PHONE_2677] Email: [EMAIL_2351]  Christina Master, MD Department of Pediatrics, Division of General Pediatrics Department of Surgery, Division of Orthopedics The Children’s Hospi[INVESTIGATOR_117729]: [PHONE_2678] Email: [EMAIL_2352]  Kristy B. Arbogast The Children’s Hospi[INVESTIGATOR_6684] [ADDRESS_131339] Philadelphia, PA [ZIP_CODE] Phone: [PHONE_2679] Email: [EMAIL_2353]     
  Protocol No. 13-101227      
04/06/2018 V 0.16  iii  TABLE OF CONTENTS Table of Contents .................................................................................................................. iii	Abbreviations and Definitions of Terms ............................................................................. vi	Protocol Synopsis ................................................................................................................. vii	Table 1: Schedule of Study Procedures .............................................................................. xi	[ADDRESS_131340]-Concussion ................................................................... 6	2.5.5	Branched Chain Amino Acids .......................................................................................................... 6	2.6	COMPLIANCE STATEMENT ....................................................................................................................... 6	3	STUDY OBJECTIVES ................................................................................................................................. 8	3.1	PRIMARY OBJECTIVE ................................................................................................................................ 8	3.2	SECONDARY OBJECTIVES ......................................................................................................................... 8	4	INVESTIGATIONAL PLAN ...................................................................................................................... 9	4.1	GENERAL SCHEMA OF STUDY DESIGN ..................................................................................................... 9	4.1.1	Screening Phase ............................................................................................................................... 9	4.1.2	Study Treatment Phase ..................................................................................................................... 9	4.2	ALLOCATION TO TREATMENT GROUPS AND BLINDING .......................................................................... 10	4.3	STUDY DURATION, ENROLLMENT AND NUMBER OF SITES .................................................................... 10	4.3.1	Duration of Study Participation ..................................................................................................... 10	4.3.2	Total Number of Study Sites/Total Number of Subjects Projected ................................................ [ADDRESS_131341] COMPLETION/WITHDRAWAL ................................................................................................... 13	5.7	EARLY TERMINATION STUDY VISIT ....................................................................................................... 14	6	STUDY EVALUATIONS AND MEASUREMENTS .............................................................................. 15	6.1	SCREENING AND MONITORING EVALUATIONS AND MEASUREMENTS .................................................... 15	6.1.1	Demographics ................................................................................................................................ 15	
  Protocol No. 13-101227      
04/06/2018 V 0.16  iv 6.1.2	Concussion History ........................................................................................................................ 15	6.1.3	Height and weight .......................................................................................................................... 15	6.1.4	Laboratory Evaluations ................................................................................................................. 15	6.2	EFFICACY EVALUATIONS ....................................................................................................................... 15	6.2.1	Axon Sports Computerized Cognitive Assessment Tool (CCAT) ................................................... 15	6.2.2	Clinical Symptoms Checklists ........................................................................................................ 16	6.2.3	Cognitive and Physical Activity Assessments ................................................................................ 16	6.2.4	Actigraphy Sleep and Assessment .................................................................................................. 16	6.2.5	Computerized Dynamic Posturography (CDP) ............................................................................. 17	6.3	SAFETY EVALUATION ............................................................................................................................ 17	7	STATISTICAL CONSIDERATIONS ...................................................................................................... 18	7.1	PRIMARY ENDPOINTS ............................................................................................................................. 18	7.2	SECONDARY ENDPOINTS ........................................................................................................................ 18	7.3	STATISTICAL METHODS ......................................................................................................................... 18	7.3.1	Baseline Data ................................................................................................................................. 18	7.3.2	Primary Efficacy Analysis .............................................................................................................. 18	7.3.3	Analysis of Secondary Endpoints ................................................................................................... 20	7.3.4	Safety Analysis ............................................................................................................................... 21	7.4	SAMPLE SIZE AND POWER ...................................................................................................................... 21	8	STUDY MEDICATION ............................................................................................................................. 22	8.1	DESCRIPTION .......................................................................................................................................... 22	8.1.1	Packaging ....................................................................................................................................... 22	8.1.2	Labeling ......................................................................................................................................... 22	8.1.3	Dosing ............................................................................................................................................ 22	8.1.4	Treatment Compliance and Adherence .......................................................................................... 23	8.1.5	Drug Accountability ....................................................................................................................... 23	9	SAFETY MANAGEMENT ....................................................................................................................... 25	9.1	CLINICAL ADVERSE EVENTS .................................................................................................................. 25	9.2	ADVERSE EVENT REPORTING ................................................................................................................. 25	9.3	DEFINITION OF AN ADVERSE EVENT ...................................................................................................... 25	9.4	DEFINITION OF A SERIOUS ADVERSE EVENT (SAE) ............................................................................... 26	9.4.1	Relationship of Serious Adverse Events to Study Drug or Other Intervention .............................. 26	9.5	IRB/IEC NOTIFICATION OF SERIOUS ADVERSE EVENTS AND OTHER UNANTICIPATED PROBLEMS ....... 26	9.5.1	Follow-up report ............................................................................................................................ 27	9.6	INVESTIGATOR REPORTING OF A SERIOUS ADVERSE EVENT TO SPONSOR ............................................. 27	9.7	MEDICAL EMERGENCIES ........................................................................................................................ 27	10	STUDY ADMINISTRATION ................................................................................................................. 28	10.1	TREATMENT ASSIGNMENT METHODS .................................................................................................. 28	10.1.1	Randomization ............................................................................................................................. 28	10.1.2	Blinding ........................................................................................................................................ 28	10.1.3	Unblinding ................................................................................................................................... 28	10.2	DATA COLLECTION AND MANAGEMENT .............................................................................................. 28	10.3	CONFIDENTIALITY ................................................................................................................................ 30	10.4	REGULATORY AND ETHICAL CONSIDERATIONS ................................................................................... 30	10.4.1	Data and Safety Monitoring Plan ................................................................................................ 30	10.4.2	Risk Assessment ............................................................................................................................ 31	10.4.3	Potential Benefits of Trial Participation ...................................................................................... 31	10.4.4	Risk-Benefit Assessment ............................................................................................................... 31	10.5	RECRUITMENT STRATEGY .................................................................................................................... 31	10.6	INFORMED CONSENT/ASSENT AND HIPAA AUTHORIZATION .............................................................. 33	
  Protocol No. 13-101227      
04/06/2018 V 0.16  v 10.7	PAYMENT TO SUBJECTS/FAMILIES ....................................................................................................... 33	10.7.1	Reimbursement for travel, parking and meals ............................................................................. 33	11	PUBLICATION ........................................................................................................................................ 34	12	REFERENCES .......................................................................................................................................... 35	13	APPENDICES ........................................................................................................................................... 38	13.1	APPENDIX 1: CLINICAL SYMPTOM CHECKLIST ................................................................................. 38	13.2	APPENDIX 2: PHYSICAL AND COGNITIVE ACTIVITY ASSESSMENTS .................................................. 39	13.3	APPENDIX 3: SLEEP ASSESSMENT ..................................................................................................... 40	13.4	APPENDIX 4: DRUG ACCOUNTABILITY ASSESSMENT ......................................................................... 41	 
  Protocol No. 13-101227      
04/06/2018 V 0.16  vi ABBREVIATIONS AND DEFINITIONS OF TERMS BCAA’s  Branched chain amino acids MRI  Magnetic resonance imaging g  Grams g/d  Grams per day mg/d  Milligrams per day CCAT  Computerized cognitive assessment tool TBI  Traumatic brain injury LFPL  Lateral fluid percussion injury HIPAA  Health Insurance Portability and Accountability Act IRB  Institutional Review Board IDS  Investigational Drug Service SAE  Serious adverse event AE  Adverse event CRCU  Clinical research computing unit CHOP  Children’s Hospi[INVESTIGATOR_117731]-aminobutyric acid DRS  Disability rating scale CRF  Case report form BMI  Body mass index PHI  Personal health information DMS  Data management system PI  [INVESTIGATOR_117732]. 13-101227      
04/06/2018 V 0.16  vii PROTOCOL SYNOPSIS Study Title HIT HEADS Trial: Head Injury Treatment with Healthy and Advanced Dietary Supplements: A randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAA’s) in the treatment of concussion Funder Dana Foundation Clinical Phase Phase II Study Rationale Annually, between 100,[ADDRESS_131342] enduring cognitive and neurobehavioral problems. Concussion is a heterogeneous insult to the brain that precipi[INVESTIGATOR_14263] a complex pathophysiological process that can result in a cascade of deleterious side effects. At present, there are no proven therapi[INVESTIGATOR_117733]. The limbic hippocampus, a brain structure crucial for learning and memory, is often damaged in concussion. In preclinical studies in our laboratory, analysis of ipsilateral hippocampi [INVESTIGATOR_117734] (TBI) demonstrated that only the concentrations of the three BCAA’s (valine, isoleucine, and leucine) were significantly altered (reduced) after injury. When these brain-injured animals received dietary supplementation with BCAA’s, the concentrations of these amino acids were restored in the injured hippocampus and the injured animals demonstrated significant cognitive improvement to levels comparable to those obtained in non-injured control animals.  In light of these results and the increasing awareness and morbidity associated with concussion, we are proposing a pi[INVESTIGATOR_117735]’s in reducing the neurocognitive side effects of concussion injury. Study Objective(s) Primary  • To determine whether, compared to placebo treatment, administration of BCAA’s, at one or more doses, after a concussion improves processing speed recovery at one or more time-periods post concussion. Secondary • Determine whether administration of BCAA’s improves neurocognitive recovery compared to placebo for the cognitive domains of attention, learning, and working memory. 
  Protocol No. 13-101227      
04/06/2018 V 0.16  viii • Evaluate whether BCAA supplementation improves clinical symptom resolution. • Determine whether BCAA supplementation reduces the time to return to normal activities, specifically school or work, and participation in sports. • Assess dose-related compliance of subjects with daily self-administration of BCAA’s and with completion of study endpoints. • Assess feasibility of enrolling potential subjects within 72 hours of concussion injury. • Assess safety of BCAA supplementation in concussed subjects. Test Article(s) The three BCAA’s—valine, isoleucine, and leucine—will be combined together in a 1:1:1 ratio and administered twice daily by [CONTACT_1966]. Study Design  This study is a randomized, placebo-controlled, double-blinded therapeutic exploratory clinical trial to evaluate the effects of BCAA’s on the recovery from the neurocognitive side effects of concussion injury. Subject Population  key criteria for Inclusion and  Exclusion: Inclusion Criteria 1. Males and females, ages [ADDRESS_131343], or for subjects <18 years old both informed consent by a parent/guardian and child assent. Exclusion Criteria 1. Witnessed seizure at the time of injury or penetrating head injury. 2. Prior concussion or TBI within 90 days. 3. Concussion or TBI severe enough to require admission to an intensive care unit for observation or intervention, specifically for the brain injury. 4. Previous history of TBI or concussion requiring admission to the hospi[INVESTIGATOR_307], disabling stroke, epi[INVESTIGATOR_002], brain tumor, neurodegenerative condition, or psychiatric disease. 
  Protocol No. 13-101227      
04/06/2018 V 0.16  ix 5. Subjects taking neurological or psychoactive medications as a regular daily prescription medication. 6. Known history of maple syrup urine disease or known family history of maple syrup urine disease.  7. Any investigational drug use within 30 days prior to enrollment. 8. Allergy to FD&C Red #40 (red dye 40) or Sucralose. 9. Lactating females.  10. Parents/guardians or subjects who, in the opi[INVESTIGATOR_7372], may be non-compliant with study schedules or procedures.  Number Of Subjects   The study will be conducted through the Children’s Hospi[INVESTIGATOR_6684].  Recruitment will stop when approximately 72subjects are enrolled. It is expected that approximately [ADDRESS_131344] approximately 2 years. Study Phases Screening Study Treatment (1) Screening: Physicians who evaluate patients with concussion will identify potential subjects. Subjects will be screened using the protocol inclusion and exclusion criteria. Informed consent and, if applicable, parental/guardian consent and child assent, will be obtained. (2) Intervention: Subjects will be randomized to receive either oral BCAA’s 7.5, 15, 22.5, or 27 grams twice daily or placebo for a total of 21 days. Efficacy Evaluations Neurocognitive function will be assessed daily through the Axon Sports computerized cognitive battery, which measures processing speed, attention, learning, and working memory. Performance will be measured primarily through reaction time data, but task accuracy data will be analyzed as well.  Clinical symptoms will be assessed through clinical symptom checklists, actigraphy (sleep), and dynamic posturography (balance testing optional). Safety Evaluations The research coordinator will ask subjects about the occurrence of any adverse events (AE’s) during the study visits conducted on days 5-9, 12-16, 22-24. A standardized question will be asked of every subject to inquire about illnesses or accidents since the previous reporting period. Statistical And Analytic Plan The mean trajectory in decline and recovery in processing speed is unknown at this stage of development. Thus, the primary analysis will aim to determine whether there are differences in processing speed between the BCAA dose groups and placebo, and if so, at 
  Protocol No. 13-101227      
04/06/[ADDRESS_131345] as the Independent Medical Monitor for this study. 
 xi      
04/06/2018 V 0.16  TABLE 1: SCHEDULE OF STUDY PROCEDURES  Evaluation Screening Day 0 Treatment Phase Days 0 – 21 Informed Consent/Assent Review Inclusion/Exclusion Criteria  Pregnancy Test on Post-Menarchal Females X  Demographics Concussion History Randomization  X Axon Sports CCAT  Daily Clinical Symptom Checklist  Daily Cognitive and Physical Activity Assessments  Daily Sleep Assessment  Daily Drug Accountability Assessment  Daily Actigraphy  Continuous Computerized Dynamic Posturography (Optional)  Days 0-4, 5-9, 12-16 Adherence Assessment  Days 0, 5-9, 12-16 Adverse Event Assessment  Days 5-9, 12-16, 22-24    
 xii      
04/06/2018 V 0.16   1 KEY STUDY PERSONNEL  Principal Investigator:  [INVESTIGATOR_117728], MD, MSCE Attending Physician, Division of Emergency Medicine, CHOP Phone: [PHONE_2680] Email: [EMAIL_2349]  Co-Investigator and IND Sponsor: Akiva Cohen, PhD  Associate [CONTACT_117807] of Pediatrics and Neurology, CHOP Phone [PHONE_2676] Email: [EMAIL_2354]  Co-Investigator: Matthew Kirschen, MD PhD Attending Physician, Department of Anesthesia and Critical Care Attending Physician, Division of Neurology, Department of Pediatrics Phone: ([PHONE_2677] Email: [EMAIL_2351]  Co-Investigator: Christina Master, MD Attending Physician, Department of Pediatrics, Division of General Pediatrics Attending Physician, Department of Surgery, Division of Orthopedics Phone: [PHONE_2678] Email: [EMAIL_2352]  Co-Investigator: Brian Sennett, MD Attending Physician, Department of Orthopaedic Surgery University of Pennsylvania Health System Phone: [PHONE_2681] Email: [EMAIL_2355]  Co-Investigator: Peter Le Roux, MD FACS The Brain and Spi[INVESTIGATOR_117736], Lankenau Medical Center    Statistician: Mary Putt, PhD Associate Professor, Department of Biostatistics and Epi[INVESTIGATOR_623], University of Pennsylvania Perelman School of Medicine Database Administrators: Shawn Ballard, MS Technical Director, Software Systems Development, Research Technologies Independent Medical Monitor: Rebecca Ichord, MD Study Pharmacist: Kenneth Rockwell, PharmD  
 xiii      
04/06/2018 V 0.16    
  Protocol No. 13-101227    
04/06/[ADDRESS_131346] sports like soccer, lacrosse, hockey, rugby, and basketball and in pursuits such as horseback riding, cycling, roller-blading, and boxing among others. No concussion is without consequences. In the short-term, patients’ cognitive and athletic performance may suffer. In the long term, concussions, and perhaps even sub-concussive blows, are thought to cause alterations in cerebral structures and functions that can lead to impaired cognitive functioning and neurobehavioral problems. That is, there are enduring deleterious effects and a potential causal link between concussion and later-life cognitive and behavioral difficulties including a condition now known as chronic traumatic encephalopathy. Concussion is a heterogeneous insult to the brain, induced by [CONTACT_117763], that precipi[INVESTIGATOR_14263] a complex pathophysiological process that can result in a cascade of deleterious side effects. Currently, there are no proven therapi[INVESTIGATOR_117733]. Preclinical studies in mice from our laboratory have demonstrated that the hippocampus, a brain structure involved in higher cognitive function often injured in concussion, has reduced levels of the three branched chain amino acids (BCAA’s)—valine, isoleucine, and leucine— after traumatic brain injury (TBI).2 In vivo administration of BCAA’s restored the concentrations of these amino acids in the hippocampus, and these animals demonstrated cognitive recovery to levels comparable to non-injured animals. In light of these pre-clinical results and the increasing awareness of morbidity, including long-term sequela, associated with concussion, we propose a pi[INVESTIGATOR_117737]’s to reduce the neurocognitive effects of concussion. 2.[ADDRESS_131347] or Intervention The three BCAA’s—valine, isoleucine, and leucine—will be combined together in a 1:1:1 ratio.  Four different dose levels will be evaluated: originally,15 g/d, 30 g/d, 45 g/d, and 60 g/d were planned, however during the original course of the study precipi[INVESTIGATOR_117738] a lower concentration than expected due to the presence of the other solutes. After further testing, it was determined that the product remained in solution at a concentration of 27g/591ml bottle and therefore, the highest dose level was altered to give four dose levels of 15g/d, 30g/d, 45g/d, and 54g/d.  Sodium gluconate, sucralose, and fruit punch concentrate are added to improve palatability. 
  Protocol No. 13-101227    
04/06/2018 V 0.16  2 2.3 Findings from Non-Clinical and Clinical Studies  2.3.1 Non-Clinical Studies Akiva Cohen, a Co-Investigator on this proposal, has directed the preclinical animal studies leading to this clinical trial. The central hypothesis of this work is that the restoration of the delicate balance of excitation and inhibition in central nervous system (CNS) synaptic circuits after TBI may improve cognitive functioning. To examine potential changes in the excitatory (glutamate) and inhibitory (gamma-aminobutyric acid or GABA) neurotransmitters after TBI, [CONTACT_26021] and colleagues used high pressure liquid chromatography (HPLC) to quantify these amino acid levels in the hippocampal formation of mice (adult male C57Bl/J6) after experimental TBI using lateral fluid percussion injury (LFPI).1 Results indicated that LPFI does not alter the concentrations of glutamate and GABA, but instead reduces the concentrations of the BCAA’s, valine, isoleucine, and leucine, by 50.8, 21.1, and 52.3%, respectively in the ipsilateral hippocampus. No other amino acid was affected and BCAA levels in the LFPI [INVESTIGATOR_117739]. After quantifying these changes in BCAA levels after brain injury, further research investigated the feasibility of using dietary treatment to restore the amino acid profile in the hippocampal formation.  Therefore, both LFPI [INVESTIGATOR_117740] (control) or contained a cocktail of all three BCAA’s (100 mM of each leucine, isoleucine and valine). After consuming the treatment for 5 days, the ipsilateral hippocampus demonstrated BCAA levels similar to those from sham animals.  Furthermore, neither injury nor BCAA treatment after injury appeared to significantly alter the remaining 14 tested amino acids, raise BCAA levels in contralateral hippocampus or hippocampi [INVESTIGATOR_117741], or alter the blood amino acid profile. LFPI [INVESTIGATOR_117742] a significant 39.0% reduction in cognitive performance (as tested by [CONTACT_117764]) when compared to uninjured mice. When the LFPI [INVESTIGATOR_117743], their cognitive performance returned to values seen in sham-injured animals. Additionally, BCAA treatment restored excitability in injured hippocampi [INVESTIGATOR_117744]. Furthermore, there was a perfect (100%) correlation between BCAA-induced cognitive improvement and restoration of ipsilateral hippocampal excitability. To our knowledge, this is the first study to identify an efficacious dietary supplement that generates a measurable change in hippocampal excitability in injured brains and, in so doing, improves cognitive function. 2.3.2 Clinical Studies [IP_ADDRESS] Clinical Studies in Adults Dietary BCAA administration has been studied extensively in healthy people and in a variety of disease states over many decades.[ADDRESS_131348] been treated with BCAA’s for variable lengths of time including for more than 2 years. In addition, many athletes and body-builders consume BCAA’s as nutritional supplements.   
  Protocol No. 13-101227    
04/06/[ADDRESS_131349] examined BCAA’s in humans after TBI.  Plasma levels of BCAA’s and their circulating metabolites are decreased within 24 hours after injury in both mild and severe TBI relative to healthy volunteers.4  One study, evaluating plasma amino acid concentrations in patients approximately 2 months after TBI, found significantly reduced levels of BCAA’s, among other amino acids, relative to age-matched, non-injured controls.5 A follow-up study on a subsequent cohort of TBI patients found that plasma concentrations of amino acids were still reduced 120 days after injury, mainly driven by [CONTACT_117765].6  Work by [CONTACT_117766] (DRS) scores when compared to placebo.7  Additionally, they showed that BCAA’s may improve recovery from a posttraumatic vegetative or minimally conscious state.8 [IP_ADDRESS] Clinical Studies in Children The lower age limit for enrollment in the proposed study is [ADDRESS_131350] been performed with BCAA’s in children.  BCAA’s were given to healthy children 9 and children with cholestatic liver disease 10 to determine daily BCAA requirements.  BCAA’s have been administered safely to children with phenylketonuria in an attempt to inhibit entry of phenylalanine into the brain and reduce its toxic effects on the CNS.11-[ADDRESS_131351] formula.14,15  Symptoms of tardive dyskinesia were reduced in children and adolescents after treatment with BCAA’s and epi[INVESTIGATOR_117745] 20 g/d of BCAA in conjunction with a ketogenic diet showed reduction in seizure frequency and improvements in behavior and cognitive functioning.16,17  In all studies of children and adolescents treated with BCAA’s, the supplements were well tolerated and without side effects. 2.4 Selection of Drugs and Dosages Work from our laboratory has demonstrated that administering the equivalent of 60 g/d of BCAA’s (in a 1:1:1 ratio of leucine, isoleucine, and valine) mitigates injury-induced anterograde cognitive impairments in our mouse model. Higher doses did not offer any additional benefit the animals.  We originally used this dose as the maximal dose in our study, noting that it is within the ranges described in previous clinical studies.3  For example, oral doses of 60 g/d are effective in reducing mania symptoms.18  Benefit has also been seen in tardive dyskinesia (~15 g/d),19 spi[INVESTIGATOR_117746] (6 g/d),20 anorexia in cancer patients (14 g/d),21 and hepatic encephalopathy (median amount of BCAA’s over 11 randomized trials was 28 g/d; range 11 to 57 g/d).22  Aquilani and colleagues demonstrated that intravenous administration of 20 g of BCAA’s over [ADDRESS_131352] that orally administering 30 g/d of BCAA’s twice daily will be safe and well tolerated.  However, during the original course of the study precipi[INVESTIGATOR_117738] a lower concentration than expected due to the presence of the other solutes. After further testing, it was determined that the product remained in solution at a concentration of 27g/591ml bottle and therefore, the highest dose level was altered to 54 g/d. 
  Protocol No. 13-101227    
04/06/2018 V 0.16  4 Overall, BCAA’s are well tolerated and associated with minimal to no side effects. Several review papers have examined BCAA administration and summarized the adverse events (AE’s). 3,22 Many studies do not comment specifically on side effects, while others contain statements like “none of the subjects experienced side effects.”  A few report mild gastrointestinal side effects such as abdominal distention, diarrhea, and constipation.  One study of patients with liver cirrhosis, a group different from our proposed study population, found these symptoms in 12% of their BCAA treatment group.[ADDRESS_131353] been reported.  These studies generally indicate that humans can consume amounts of BCAA’s that are comparable to those proposed here, without AE’s.  Indeed, many body-builders and athletes consume large amounts of BCAA’s as nutritional supplements in various formulations.  There is a theoretical concern that because BCAA’s can alter the levels of other neurotransmitters, like dopamine and serotonin, depression or impairment of some cognitive functions may occur in susceptible individuals.  These symptoms, however, have never been reported clinically.  It should be noted that the daily intake of BCAA’s in a 70 kg person consuming the recommended dietary allowance for protein (0.8 g/kg/d) would be 8.4 –11.2 g [40 kg person would be 4.8 - 6.4g].  In athletes, for whom a common recommendation is at least 1.2 g protein/kg/d, the daily BCAA intake would be 12.6 – 16.8 g [40 kg person would be 7.2 – 9.6g].  The recommended dietary allowance of protein in adolescents is slightly higher than adults (1.0 g/kg/d for 11-14 year olds and 0.8-0.9 for 15-19 year olds). Therefore a 40 kg younger adolescent consuming the recommended dietary allowance for a non-athlete would be 6.0 – 8.0g and athlete would be 9.0 – 12.0g. While some studies in patients with liver cirrhosis [ADDRESS_131354] used doses >100 g/d without reported side effects, the highest dose used in studies of neurological disease has been 60 g/d.  Additionally, a single dose finding study has been done in 12 healthy volunteers and showed in a randomized, double blind, crossover design that single oral doses of 10 g, 30 g and 60 g of BCAA’s were safe and well tolerated.25  At 60 g/d, this dose represents a 2 to 4 fold increase in the daily BCAA intake for athletes (assuming a body weight of 70 kg). Given that this dose is safe and well tolerated in humans, the no observable adverse effect level (NOAEL) of BCAA intake may be considerably higher, although this has not been formally studied to our knowledge. A toxicity study in rats over [ADDRESS_131355] measures of potential toxicity at doses greater than 100 g/d.[ADDRESS_131356] both obvious and subtle impairments in cognitive functioning after concussion.  Several computerized testing batteries are commercially available to evaluate patients after concussion.  The Axon Sports Computerized Cognitive Assessment Tool (CCAT) is optimal for use in a context where frequent repeated measurements of cognitive performance are required.  The CCAT consists of four computerized cognitive tests, derived from theoretical and developmentally sensitive principles, allowing this tool to be sensitive to any cause of cognitive performance change in individuals over time. The tasks themselves measure processing speed (via a simple reaction time task), attention (via a choice reaction time task), learning (via a one card learning task), 
  Protocol No. 13-101227    
04/06/2018 V 0.16  5 and working memory (via a one-back task).  These tests have been widely validated in both healthy and concussed individuals.  Normative scores exist for men and women greater than [ADDRESS_131357] demonstrated that the Axon Sports CCAT has minimal practice effects (making it ideal for repeat testing as in this proposal), and good criterion, construct, test-retest, and ecological validity.33,[ADDRESS_131358] validity of a 9-item self-reported symptom instrument in both high school and college athletes.44  The items are: headache, nausea, balance problems, sleepi[INVESTIGATOR_4460], drowsiness, fatigue, feeling “slowed down”, feeling “in a fog”, and difficulty concentrating.  This 9-item Head Injury Scale is a summative 7-point Likert-type scale instrument designed to measure the overall duration (length of symptom experienced over a 24-hour period) of concussion-related symptoms.  Pi[INVESTIGATOR_117747] 9 symptoms has felt during the previous 24-hour period (i.e. symptom severity scale). 2.5.[ADDRESS_131359]-Concussion Sleep disturbances are reported in up to 72% of patients with mild, moderate, and severe TBI up to three years post-injury.  Those TBI patients with sleep disturbances have longer inpatient hospi[INVESTIGATOR_7959], a higher cost of rehabilitation, and a greater rate of functional disability. Current clinical practice guidelines advocate aggressive management of sleep hygiene after TBI to improve neurological symptoms and cognitive outcomes; however, the evidence behind this is lacking, and the neural mechanisms underlying sleep disturbances after TBI are unknown.  Moreover, our current therapeutic options for sleep disturbances are less effective in patients with TBI-related sleep problems than with other sleep disorders.  Preliminary data from our laboratory suggest that after LFPI, mice show significant sleep disturbances for up to [ADDRESS_131360]-injury compared to sham surgery controls, including more time sleepi[INVESTIGATOR_117748] (defined by [CONTACT_117767]-wake transitions and shortened average length of sleep and wake bouts).  BCAA supplementation seems to attenuate some of these sleep disturbances after TBI.   
  Protocol No. 13-101227    
04/06/[ADDRESS_131361]-Concussion Balance or postural control is necessary in activities of daily living and sport.  Balance requires the CNS to process and integrate afferent information from the visual, somatosensory (proprioceptive), and vestibular systems to then perform coordinated musculoskeletal responses.  Abnormal static and dynamic balance is well described in survivors of TBI and altered postural dynamics is frequently found immediately after a concussive injury.  Balance deficits usually resolve within [ADDRESS_131362] of balance testing since they attempt to objectively measure balance.  The computerized dynamic posturography (CDP) test as an objective means to assess balance by [CONTACT_117768], multimodal sensory stimulation.[ADDRESS_131363] be acquired through the diet.  They are involved in numerous functions in the human brain including protein synthesis and energy production.  A significant fraction of ingested BCAA’s is not metabolized by [CONTACT_117769], causing plasma concentrations to rise appreciably.  BCAA’s are important for protein metabolism throughout the body. They are transported into the brain by [CONTACT_117770], low capacity transporters, located at the blood–brain barrier on capi[INVESTIGATOR_117749].  Leucine enters the brain faster than any other amino acid, but valine and isoleucine also readily cross the blood-brain barrier. Once in the brain, BCAA’s are key amino acids involved in de novo glutamate (the major excitatory neurotransmitter in the CNS) synthesis, as approximately 50% of brain glutamate contains BCAA-derived nitrogen.  Furthermore, de novo glutamate synthesis contributes approximately 40% of the releasable synaptic glutamate. It is believed that astrocytes remove released glutamate from the synaptic cleft, and amidate it to form glutamine for return to the neuron. This process, known as the glutamate:glutamine cycle, requires de novo glutamate synthesis to maintain sufficient presynaptic releasable neurotransmitter pools.  If this process continued unabated, it would lead to a net transfer of nitrogen from astrocytes to neurons.  Nature prevents this by [CONTACT_117771]’s in the opposite direction (i.e., from the neuron to the astrocyte).  Due to the intrinsic role for BCAA’s in glutamate and subsequent GABA (the major inhibitory neurotransmitter in the mammalian CNS) synthesis, and the interrelationship between the glutamate:glutamine cycle and the presumed BCAA-dependent astroglial:neuronal nitrogen shuttle, changes in these three specific amino acids likely contribute to post-traumatic alterations in both hippocampal excitability and cognitive performance. 2.6 Compliance Statement This study will be conducted in full accordance with all applicable Children’s Hospi[INVESTIGATOR_6684] (CHOP) Research Policies and Procedures and all applicable federal and state laws and regulations. The investigators will perform the study in accordance with this 
  Protocol No. 13-101227    
04/06/2018 V 0.16  7 protocol, will obtain consent and assent, and will report unanticipated problems involving risks to subjects or others in accordance with CHOP’s Institutional Review Board (IRB) Policies and Procedures and all federal requirements. Collection, recording, and reporting of data will be accurate and will ensure the privacy, health, and welfare of research subjects during and after the study.  
  Protocol No. 13-101227    
04/06/2018 V 0.16  8 3 STUDY OBJECTIVES The purpose of this study is to determine whether dietary administration of BCAA’s shows evidence of improving the recovery of neurocognitive symptoms after concussion injury, and to determine which of several doses of dietary BCAA’s shows the highest promise of efficacy. 3.1 Primary Objective The primary objective of this study is to determine whether, compared to placebo treatment, administration of BCAA’s, at one or more doses, after a concussion improves processing speed recovery at one or more time-periods post concussion.  In the event that differences are observed, we will determine whether differences in processing speed between BCAA-treated and placebo-treated groups reflect differences in the maximum level of impairment and/or increases in the subsequent speed of improvement. 3.2 Secondary Objectives The secondary objectives are to: • Determine whether administration of BCAA’s improves neurocognitive recovery compared to placebo for the cognitive domains of attention, learning, and working memory, and if so determine whether the results reflect differences in maximum levels of impairment or increases in subsequent speed of improvement. • Evaluate whether BCAA supplementation improves clinical symptom resolution. • Determine whether BCAA supplementation reduces the time to return to normal activities, specifically school or work, and participation in sports. • Assess dose-related compliance of subjects with daily self-administration of BCAA’s and with completion of study endpoints. • Assess feasibility of enrolling potential subjects within 72 hours of concussion injury. • Assess safety of BCAA supplementation in concussed patients. 
  Protocol No. 13-101227    
04/06/2018 V 0.16  9 4 INVESTIGATIONAL PLAN 4.1 General Schema of Study Design The proposed study is a therapeutic exploratory clinical trial that will evaluate the effects of BCAA’s on the magnitude and recovery of neurocognitive deficits following concussion injury. 4.1.[ADDRESS_131364] experience in diagnosing concussion, will identify potential subjects.  The investigators and co-investigators will inform the groups of physicians who will be referring patients to the study (e.g. CHOP and Penn Sports Medicine, CHOP and HUP Emergency Medicine) about the study procedures and their role in referring patients via email and presentations at local conferences.  For these groups of physicians, the diagnosis of concussion is informed by [CONTACT_117772].  The most widely used is the Consensus Statement on Concussion in Sport: The 5th International Conference on Concussion in Sport, Berlin, October 2016.[ADDRESS_131365] a concussion. The source document and documentation of the PI’s review and confirmation of the diagnosis will be maintained in the subject’s file.  Potentially eligible subjects will be referred to the study coordinator and subsequently screened by a study staff member using the protocol inclusion and exclusion criteria during an in-person interview.  Post-menarchal females will have a urine pregnancy test performed, or documented as negative within 72 hours prior to enrollment.  Informed consent and, if applicable, parental/guardian consent and child assent, will be obtained prior to any study related procedures being performed.  If enrolled, subjects will be randomized to receive one of four different dose levels of BCAA’s or placebo.  4.1.2 Study Treatment Phase Subjects enrolled in the trial will be randomized to receive either oral BCAA’s at doses of 7.5, 15, 22.5, or 27 g BID or an oral placebo BID for a total of 21 days. Subjects will complete five on-line computerized assessments daily:  1. Axon Sports Computerized Cognitive Assessment Tool 2. Clinical symptom checklists (Appendix 1) 
  Protocol No. 13-101227    
04/06/2018 V 0.16  10 3. Cognitive and physical activity assessments (Appendix 2) 4. Sleep assessment (Appendix 3) 5. Drug accountability assessment (Appendix 4)  Subjects will wear an actigraphy monitor for the duration of the trial to assess sleep patterns.  Computerized Dynamic Posturography may be conducted at 3 time points (days 0-4, 5-9, and 12-16) during the study treatment phase. 4.[ADDRESS_131366]. Putt, will generate a randomization schedule for implementation in the randomization module of the study database system. The randomization scheme will be based on an equal allocation of each of the possible doses or placebo, and stratified based on sex.  The randomization schedule is uploaded into the data management system (DMS) and provided to the Investigational Drug Service (IDS).  The IDS will use the randomization schedule to prepare kits of BCAA doses or placebo for distribution.  Upon confirmation of eligibility, the DMS will provide study personnel with a number that is then given to the IDS and corresponds to the kit number to be distributed.  All study team members will be blinded to treatment assignment. The Database Administrator will have access to the link between the kit number and the treatment arm and will provide this information to the Investigational Drug Service (IDS) so that kits are prepared according to this scheme. BCAA and placebo treatment kits will appear identical. 4.[ADDRESS_131367] will be up to 22 days, with up to 1 day screening and up to 21 days in the treatment phase.  4.3.2 Total Number of Study Sites/Total Number of Subjects Projected The study will be conducted through the Children’s Hospi[INVESTIGATOR_117750].  Recruitment will stop when [ADDRESS_131368] day 10 of the study. It is expected that approximately 72 subjects will be enrolled to produce 50 such subjects.  All subjects who enroll and receive study medication will be evaluable for safety.  4.4 Study Population 4.4.1 Inclusion Criteria 1) Males and females, ages 11 - 34 years, of any race.  2) Weight at least 40kg. 3) Subjects who had a concussion, as diagnosed by a qualified physician or advanced practice provider, within the 72 hours prior to enrollment.   4) Ability to have daily email and internet access. 
  Protocol No. 13-101227    
04/06/2018 V 0.16  11 5) Post-menarchal females must have a negative urine pregnancy test and must use an acceptable method of contraception including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive for the duration of the study. 6) Subjects must, in the opi[INVESTIGATOR_117751], have the capacity to provide informed consent, defined by: 1) the ability to communicate; 2) the ability to assess their understanding of the treatment; 3) the ability to understand the risks and benefits of the treatment; and 4) the ability to understand the risks and benefits of not embarking on the treatment. 7) Informed consent by [CONTACT_423], or for subjects <18 years old both informed consent by a parent/guardian and child assent. 4.4.2 Exclusion Criteria 1) Witnessed seizure at the time of injury or penetrating head injury. 2) Prior concussion or TBI within 90 days.   3) Concussion or TBI severe enough to require admission to an intensive care unit for observation or intervention, specifically for the traumatic brain injury.   4) Previous history of TBI or concussion requiring admission to the hospi[INVESTIGATOR_307], disabling stroke, epi[INVESTIGATOR_002], brain tumor, neurodegenerative condition, or psychiatric disease. 5) Subjects taking neurological or psychoactive medications as a regular daily prescription medication (e.g. stimulants, antidepressants, anticonvulsants, benzodiazepi[INVESTIGATOR_1651], etc.). 6) Known history of maple syrup urine disease or known family history of maple syrup urine disease.  7) Any investigational drug use within 30 days prior to enrollment. 8) Allergy to FD&C Red #40 (red dye 40) or Sucralose. 9) Lactating females.  10) Parents/guardians or subjects who, in the opi[INVESTIGATOR_7372], may be non-compliant with study schedules or procedures. Subjects that do not meet all of the enrollment criteria may not be enrolled. Any violations of these criteria must be reported in accordance with IRB Policies and Procedures.  
  Protocol No. 13-101227    
04/06/2018 V 0.16  12 5 STUDY PROCEDURES 5.1 Screening Visit • Informed consent • Review of inclusion and exclusion criteria • Urine pregnancy test (for post-menarchal females only) 5.2 Study Treatment Phase At the start of the treatment phase at Visit 1, the study coordinator or study staff member will obtain demographic information, a concussion history and measure height and weight.  The study drug will be dispensed in 42 bottles at the time of enrollment.  The assessments during the study treatment phase will be web-based and completed daily through the study website:     1. Axon Sports Computerized Cognitive Assessment Tool 2. Clinical symptom checklists (Appendix 1) 3. Cognitive and physical activity assessments (Appendix 2) 4. Sleep assessment (Appendix 3) 5. Drug accountability assessment (Appendix 4)  Subjects will wear an actigraphy monitor for the duration of the trial to assess sleep patterns.  Subjects will have the option to complete computerized dynamic posturography (CDP) measured on visits 1, 2, and 3, which correspond to study, days 0-4, 5-9 and 12-16.  If enrollment occurs on a Saturday or Sunday, CDP can be conducted the following Monday or Tuesday.  The actigraph monitor will be downloaded during the CDP visits, and after being returned at the conclusion of the study (Visit 4, Days 22-24).  Subjects will be screened for drug accountability via a urine assay on visits [ADDRESS_131369] recruitment has demonstrated issues with consistent compliance with study procedures.  Therefore, we will institute graduated rewards for continued participation during the study.  Using a token economics approach, study subjects will be rewarded by [CONTACT_3649]- or email-based reinforcement for each data entry completed, including visual representations of compliance to serve as reminders/motivators for sustained compliance.52-55  These will graphically and/or by [CONTACT_117773] 3-day-in-a-row and 7-day-in-a-row endpoints, which will have associated monetary incentives (see subject payment section).  Visit Purpose Main Procedures Duration Visit 1, Day 0 Screening  Informed consent Review inclusion/exclusion criteria Urine pregnancy test (post-menarchal women only) 15 minutes Visit 1, Day 0 Orientation Start Study Drug Orientation to study & study website Demographics & concussion history Baseline compliance urine test 2 hours 
  Protocol No. 13-101227    
04/06/2018 V 0.16  13 Computerized balance testing (optional)* Distribute actigraphy sleep monitor Distribute study drug Days 0-21 Daily assessments via study website Computerized cognitive testing Clinical symptom checklists  Cognitive & physical activity assessments  Sleep assessment 15 minutes Visit 2, Day 5-9 Routine Visit Computerized balance testing (Optional) Compliance urine test 20 minutes Visit 3, Day 12-16 Routine Visit Computerized balance testing (Optional) Compliance urine test 20 minutes Visit 4, Day 22-24 End of Study Return used and unused drug bottles Return actigraphy monitor 10 minutes * - If enrollment occurs on a Saturday or Sunday, balance testing can be conducted the following Monday or Tuesday.  5.3 Unscheduled Visits The study coordinator and investigators will be available to address any concerns or questions that may arise during the study.  Any medically related questions will be referred to their primary treating physician.  5.4 Prior and Concomitant Medications All medications used within 7 days prior to the screening visit and through the end of the study will be recorded.  The dates of administration and reason for use will be included.  Participation in the study will not preclude subjects from receiving symptomatic management for concussion related symptoms (e.g. non-steroidal anti-inflammatory drugs for headaches) or other disorders.  However subjects will be discontinued from the study if they use neurological or psychoactive medications (e.g. stimulants, antidepressants, anticonvulsants, benzodiazepi[INVESTIGATOR_1651], etc.) during the study.  While subjects will be prohibited from using dietary supplements during the study, there will be no dietary restrictions.  5.[ADDRESS_131370] Completion/Withdrawal Subjects may withdraw from the study at any time without prejudice to their care.  They may be discontinued from the study at the discretion of the investigators for safety concerns related to any adverse event.  Any subject who sustains a second concussion during the study period will be withdrawn.  Additionally, any female subject who becomes pregnant while enrolled in the study will be withdrawn. Date of termination will be documented for each subject.  
  Protocol No. 13-101227    
04/06/[ADDRESS_131371] that they return all of the study drug bottles (used and unused). 
  Protocol No. 13-101227    
04/06/2018 V 0.16  15 6 STUDY EVALUATIONS AND MEASUREMENTS 6.1 Screening and Monitoring Evaluations and Measurements 6.1.1 Demographics • Demographic characteristics will be obtained via interview: date of birth, gender, ethnicity, racial background, native language, handedness, and highest educational level attained. 6.1.2 Concussion History • Concussion history will be obtained via interview: number of times diagnosed with a concussion and date of last concussion. • History of current concussion obtained from the subject and family members, if necessary, via interview including: mechanism of injury, for sports-related concussions: sport and position and specific mechanism (head-to-head, head-to-ground, hit-to-body, etc), day and time of the injury, was the subject helmeted, presence and duration of loss of consciousness.  The subject may bring a clinic note from their referring physician and refer to it for answers to these questions if they are unsure or sustained amnesia from their concussion.  For CHOP patients, data may be collected directly from the medical record of their CHOP visits if subjects/parents are unable to provide. 6.1.[ADDRESS_131372] recent visit documentation if visit was within 1 week of enrollment. 6.1.4 Laboratory Evaluations [IP_ADDRESS] Pregnancy Testing A urine pregnancy test will be performed through the Translational Core Laboratories for all post-menarchal female subjects.  Results will be available to the study coordinator and investigators in less than 5 minutes. If the study team is unable to access Translational Core Laboratories and/or it is not possible to obtain pregnancy test results within [ADDRESS_131373] become pregnant while enrolled in the study, they will be withdrawn.  6.2 Efficacy Evaluations 6.2.1 Axon Sports Computerized Cognitive Assessment Tool (CCAT) The Axon Sports CCAT will be completed daily over an 8-10 minute period using any computer with internet access.  The CCAT consists of four computerized cognitive tests, 
  Protocol No. 13-101227    
04/06/2018 V 0.16  16 derived from theoretical and developmentally sensitive principles and aims to be sensitive to any cause of cognitive performance change in individuals over time. The tasks themselves measure processing speed (via a simple reaction time task), attention (via a choice reaction time task), learning (via a one card learning task), and working memory (via a one-back task).  All of the four tasks are based on a ‘playing-card’ paradigm. Within each of the playing-card tasks, participants are shown a pi[INVESTIGATOR_510] a playing card and asked to answer a question about the card. Different tests are created by [CONTACT_117774]. For example, in the attention test the question ‘Is the card red?’ elicits a simple binary choice and is equivalent to a choice reaction time test. The question ‘Is the card exactly the same as the previous card?’ is used in the working memory paradigm to produce a 1-back version of the commonly used n-back working memory paradigm. In all tasks, responses are indicated by [CONTACT_117775] ‘YES’ or ‘NO’ buttons on a computer keyboard. Subjects will be reminded to choose an environment with minimal distractions for completing the cognitive battery.  Subjects will complete a single short practice session, as previous research has demonstrated that a single practice test is sufficient to eliminate the majority of practice effects.  6.2.[ADDRESS_131374], designed to measure the overall duration and severity of concussion-related symptoms, will be administered daily over a 1-2 minute period via the study website. This summative 7-point Likert-type scale instrument incorporates aspects of the two scales commonly used in the literature (Post-concussion Symptom Scale [included in the Sport Concussion Assessment Tool 2 (SCAT2)] and Graded Symptom Checklist) to capture the overall severity of symptoms. The checklist will be administered twice: first to address the duration and second the severity of symptoms including headache, nausea, balance problems, sleepi[INVESTIGATOR_4460], drowsiness, fatigue, feeling “slowed down” or “in a fog”, and difficulty concentrating.   6.2.3 Cognitive and Physical Activity Assessments Subjects will be asked daily to indicate their level of cognitive and physical activity via the study website.  The physical activities are based on the “Graduated Return to Play” protocol recommended in the Consensus Statement on Concussion in Sport.  The cognitive activities are based on return to school guidelines used at CHOP. 6.2.[ADDRESS_131375] and store the data over an extended period of time.  The data are collected continuously and then translated into epochs (typi[INVESTIGATOR_897] 30 sec or 1 min) of activity.  Using validated algorithms, epochs are then scored as sleep or wake.  Subjects will be instructed to push the event button on the device each time they go to bed, get out of bed, take the watch off or put the watch back on if not permitted in 
  Protocol No. 13-101227    
04/06/2018 V 0.16  17 an academic or athletic event.  The study coordinator will download the data from the actigraph device onto a study computer at each study visit and the conclusion of the study. The actigraph monitor used in this study is called the ActiSleep+ Monitor and is produced by [CONTACT_117776], FL.  This product is approved for marketing in the US and is an FDA cleared Class II medical device within the US (see attached material).  This product is currently deployed in other concussion research studies at CHOP.  6.2.5 Computerized Dynamic Posturography (CDP) Computerized dynamic posturography (CDP) will be measured over a [ADDRESS_131376] of CDP evaluates a person’s ability to effectively utilize the visual, somatosensory, and vestibular systems for the maintenance of balance.  It also provides information regarding the patient’s ability to maintain balance in the presence of inaccurate visual information that can confuse orientation.  The motor control test measures, time to respond to a disruption of equilibrium.  Testing is performed by [CONTACT_117777] a subject on a computerized support surface to measure their ability to sustain upright stance while the support surface and/or visual surround move in response to their own postural movements.  Six sensory conditions are performed to assess ability to use visual, proprioceptive, and vestibular information in isolation and in concert for the preservation of balance.  Medium and large forward translations for each leg will be recorded for the motor control test.  CDP will be performed on an EquiTest® system (manufactured by [CONTACT_117778]®, a division of Natus®) which is an FDA approved product.  CDP will be conducted by a trained audiologist A report will be issued to the investigators who will subsequently input the results into the study database. Balance testing is now available at CHOP, as of fall 2017, and if equivalence can be determined between the results gathered at HUP and CHOP and access can be gained to this equipment/lab then CHOP will also be added as a potential site for balance testing of subjects. 6.[ADDRESS_131377] safety will be monitored by [CONTACT_117779]’s.  See Section 8.1 for details. 
  Protocol No. 13-101227    
04/06/2018 V 0.16  18 7 STATISTICAL CONSIDERATIONS 7.1 Primary Endpoints We hypothesize that neurocognitive function in concussed subjects will initially worsen and then improve in a non-linear fashion over the course of the study, and that, compared to the placebo group, one or more of the BCAA dose level groups will show a reduced nadir in cognitive performance and/or a more rapid recovery.  Currently, the time course of the worsening and improvement of neurocognitive function after concussion is not well understood.  Thus, part of our study will aim to identify times when maximal differences between groups may be observed. The primary analysis in this exploratory study will consider three key time periods, Days 3-6, 7-[ADDRESS_131378]. 7.2 Secondary Endpoints • Repeated measurements of neurocognitive functioning (CCAT test of attention, learning, and working memory) sampled over a period of 21 days. • Clinical symptoms. • Time to return to school/work, and sports participation. • Tolerability of BCAA’s based on AE’s. • Compliance. • Safety and incidence of AE’s and serious adverse events (SAE’s). 7.[ADDRESS_131379] statistics (e.g. means, medians, standard deviations, or proportions).  For all analyses, high dose group will continue to be evaluated together, despi[INVESTIGATOR_117752].  Subgroup analysis will be done to evaluate any differences in those subjects who received the full 60 g/d dosing before this dose was decreased, versus the current 54 g/d dosing. Graphical procedures will be used to assess distributional assumptions and particularly the assumption of normality of outcome.  7.3.[ADDRESS_131380] 10 days of the study when we anticipate that the majority of subjects will be highly compliant. We will model processing speed as a function of dose and day of study and will allow differences between dose groups to vary as a function of time through a series of interaction terms.  To ensure that the number of interaction terms does not become too large, we will consider groups of two to four time points, looking specifically at whether 
  Protocol No. 13-101227    
04/06/[ADDRESS_131381] difficulty with compliance due to their injury, or become non-compliant once their symptoms improve. As part of this feasibility study, we will explore patterns of missing data, in particular how they may relate to the observed response (e.g. more missing data in those subjects who show better or worse processing speed) to compliance (e.g. more missing data in subjects who regularly fail to consume their supplements) and to demographics e.g. gender, age.  This information will be valuable in planning future efficacy trials, and will guide our efforts to adjust for missing data.  For example if the probability of missing data is associated with outcome, then non-ignorable missing data methods will be needed, whereas missing at random assumptions will be valid if the missing data can be explained by [CONTACT_117780]. In addition to the primary analysis, this feasibility study will consider several approaches to modeling a smooth function for the trajectories of the individual processing speeds.  The first model will fit non-linear curves to the trajectory of processing speed for the dose groups 
  Protocol No. 13-101227    
04/06/[ADDRESS_131382] as we hypothesize that it represents the time when processing speed has returned to baseline. Here we anticipate a model using a quadratic with a change-point,47,48 with separate baseline functions for the dose and placebo groups and separate change-points.  Correlation between repeated measurements on the same individual over time will be modeled using random effects i.e., a mixed effects model will also be used for these analyses.  7.3.3 Analysis of Secondary Endpoints Secondary endpoints, including clinical symptoms such as the posturography and sleep assessments, and the learning, attention and working memory components of the neurocognitive battery will be modeled using a similar approach as described above for the primary efficacy analysis (Section 7.3.2), with the goal of assessing differences between groups over time, after adjustment for age differences. We will assess the distribution of the outcome and either use a transformation to achieve approximate normality or use a generalized mixed effects model. Time to event outcomes (e.g. time to return to school or sports participation) will be modeled using a Cox proportional hazards model. We will secondarily adjust our primary models for body mass index (BMI) and compliance to obtain information on whether individuals with lower BMI, and presumably higher BCAA/kg dosing have better outcome.  We will also monitor compliance including adherence to treatment and daily completion of neurocognitive testing.  It is of interest to determine whether there are differences in compliance among the dosage groups versus placebo whether compliance decreases as a function of time, and whether compliance differs among groups over time. Adherence to treatment is measured in terms of number of bottles of consumed per day (0, 1, or 2) and will be modeled as an ordinal outcome. Adherence to treatment will be assessed using generalized estimating equations (GEE) models as we have repeated measures on adherence for each subject across all time points in the study and are primarily interested in differences between groups. In particular we anticipate that with regular prompting and encouragement, subjects will consistently complete their neurocognitive functioning tests up until about 10 to 14 days into the study. We anticipate that compliance may begin to decrease around the 10 to 14 day point as subjects begin to feel better and return to their normal routines. Assessment of compliance will be key information needed to design the anticipated pi[INVESTIGATOR_117753].  
  Protocol No. 13-101227    
04/06/2018 V 0.16  21 7.3.4 Safety Analysis All subjects enrolled into the study, who receive study medication, are evaluable for safety. The frequencies of AEs by [CONTACT_24975], body system, severity, patient BMI, and relationship to study drug will be summarized. SAEs (if any) will be described in detail.  AE incidence will be summarized by [CONTACT_117781] 95% two-sided confidence intervals. 7.[ADDRESS_131383] 80% power to detect mean differences in processing speeds between the BCAA group and the placebo group on the order of 0.122 seconds. Putting this in the context of a mean processing speed for healthy individuals of ages 14 to 34 of 2.46 to 2.51 seconds (Axon Sports unpublished), means that detectable differences between groups are on the order of 5% of the mean of a healthy individual. The analysis is based on a standard deviation in healthy individuals of 0.08, which we inflated to 0.[ADDRESS_131384] Day 10 to be “evaluable for efficacy.” We conservatively anticipate that no more than 72 subjects will be enrolled in order to achieve 50 evaluable subjects.  We anticipate that it will take us approximately 12-18 months to recruit these subjects.    
  Protocol No. 13-101227    
04/06/2018 V 0.16  22 8 STUDY MEDICATION 8.1 Description The three BCAA’s, valine, isoleucine, and leucine, will be dissolved in water and combined with sodium gluconate, Tropi[INVESTIGATOR_117754]-Aid® powder, and sucralose to improve palatability.   8.1.[ADDRESS_131385] will be packaged by [CONTACT_21212] (IDS) at the Hospi[INVESTIGATOR_71971] (HUP) into 20 oz bottles containing 591 mL of blinded doses active drink (containing valine, isoleucine and leucine) or matching placebo (similar in appearance and taste but absent the three amino acids).  Each bottle will be individually labeled and sealed with a tamper-evident cap, then packaged in corrugated cartons (with a carry handle) in sets of 14 (representing a one-week supply). 8.1.[ADDRESS_131386] will carry labeling that clearly identifies the study, treatment code and directions, as well as the statement ‘Caution: For Investigational Use Only’.  Each label will identify the study day (Day 1, Day 2, etc.) and the labels will be color coded for MORNING dose (yellow) and EVENING dose (blue).  A detailed label on the outside of the carton will identify the subject, date, prescriber, emergency phone number, study, federal caution statement (noted above) and detailed directions for use.  A smaller removable label, will be placed on the carton and will be peeled off and pasted into the subject’s study records at the time of dispense, as a clear record of which kit was issued to which subject. 8.1.3 Dosing Four different doses of BCAA’s will be used in this study, 15, 30, 45, and 54 grams per day (divided BID).  Originally, 60 grams per day (divided BID) was used as the highest dose, however during the study precipi[INVESTIGATOR_117738] a lower concentration than expected in to the presence of the other solutes. After further testing, it was determined that the product remained in solution at a concentration of 27g/591ml bottle and therefore, the highest dose level was altered to 54 grams per day. For each dose, the three BCAA’s - valine, isoleucine and leucine - will be combined together in a 1:1:1 ratio and dissolved in 591 ml (20 ounces) of water (see table below).  Additionally, 13 g sodium gluconate, 1.75 g unsweetened Tropi[INVESTIGATOR_117754]-Aid powder, and 9 g sucralose are added to the mixture to improve palatability.  This mixture will be administered twice daily.   BCAA 27 g/bottle Valine 9 g Leucine 9 g Isoleucine 9 g Sodium Gluconate 13 g Unsweetened flavoring 1.75 g Sucralose 9 g BCAA 22.5 g/bottle Valine 7.5 g Leucine 7.5 g  Isoleucine 7.5 g Sodium Gluconate 13 g Unsweetened flavoring 1.75 g Sucralose 9 g BCAA 15 g/bottle Valine 5 g  Leucine 5 g  Isoleucine 5 g  Sodium Gluconate 13 g Unsweetened flavoring 1.75 g Sucralose 9 g BCAA 7.5 g/bottle Valine 2.5 g Leucine 2.5 g  Isoleucine 2.5 g Sodium Gluconate 13 g Unsweetened flavoring 1.75 g Sucralose 9 g 
  Protocol No. 13-101227    
04/06/[ADDRESS_131387] is instructed not to complete the remainder of the solution the following day and proceed to the bottles scheduled for that day.  A study member is available 24 hours per day, 7 days per week by [CONTACT_117782]. The placebo solution will contain 1.2 g sucrose octaacetate (NF grade) and 30 g of microcrystalline cellulose (NF grade) dissolved in 591 ml of water.  Additionally, 13 g sodium gluconate, 1.75 g unsweetened Tropi[INVESTIGATOR_117754]-Aid powder, and 9 g sucralose are added to the solution.  This will ensure that the placebo solution has similar taste, texture, consistency and appearance as the BCAA solution. BCAA’s will be supplied by [CONTACT_117783].  All ingredients in both BCAA and placebo solutions are USP/NF grade (see attached material). 8.1.4 Treatment Compliance and Adherence Each day, subjects will self-report the number of bottles of the study medication that were consumed the prior day.  Subjects will return all used, partially used, and unopened medication bottles at the conclusion of the study.   The study supplement will contain 500 mg/bottle of deuterium oxide that can be detected in the urine using isotope ratio mass spectrometry.  Deuterium oxide has been used to assess drug compliance in both adult and pediatric research studies.49-[ADDRESS_131388]. Cohen.  Isotope ratio mass spectrometry will be conducted by [CONTACT_117784] a batched fashion at several points throughout the study.  Deuterium oxide will be supplied by [CONTACT_117785] (see attached material). To assist with treatment compliance, subjects will be sent text, email or in-app alert messages twice a day to remind subjects to consume their study drink, and to reward them for compliance if they have documented consuming their drink.  8.1.5 Drug Accountability Adequate records of study drug receipt and disposition will be maintained by [CONTACT_117786].  Records of receipts, investigational drug orders, dispensing records, and 
  Protocol No. 13-101227    
04/06/[ADDRESS_131389] under the terms and conditions set forth in this protocol.  The study medication is to be prescribed by [CONTACT_117787].  At study completion, all study products including partially used and empty containers will be destroyed on-site by [CONTACT_117788], with copi[INVESTIGATOR_117755]/sponsor.  
  Protocol No. 13-101227    
04/06/2018 V 0.16  25 9 SAFETY MANAGEMENT 9.1 Clinical Adverse Events Clinical AE’s will be monitored throughout the study.  The study coordinator will ask the subject about the occurrence of any AE’s during the scheduled study visits conducted on days 7, 14, and [ADDRESS_131390] complete information about AE’s from subjects including: • Descriptive text and key words of the event • Assessment of the event severity (grade)  • Indication if the event is serious and type  • Relationship to study drug • Start date and end date (if applicable) The investigators, with input from the independent medical monitor, will evaluate all AE’s to determine the relationship to the study drug.  All recorded AE’s will be followed until resolution or stabilization. An AE Log will be used to collect this information across study visits and prompt follow-up of previously reported events.  Additionally, at the final study visit, subjects will be asked to call the study coordinator and report any serious AE’s that they experience following the last visit, and that they believe may be related to their treatment.   9.2 Adverse Event Reporting The investigator is responsible for recording and reporting unanticipated problems related to research that occurs during and after study treatment. All on-site SAEs (CHOP or related sites) will be reported to the IRB in accordance with CHOP IRB policies. AE’s that are not serious will be summarized in narrative or other format and submitted to the IRB at the time of continuing review.  Since this is an FDA regulated study, [CONTACT_26021] (IND Sponsor) will monitor AEs and report them to the FDA. 9.[ADDRESS_131391] who has received an intervention (drug, biologic, or other intervention). An AE is any unfavorable or unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. All AE’s (including SAE’s) will be noted in the study records and on the case report form with a full description including the nature, date and time of onset, determination of non-serious versus serious, intensity (mild, moderate, severe), duration, causality, and outcome of the event. 
  Protocol No. 13-101227    
04/06/2018 V 0.16  26 9.4 Definition of a Serious Adverse Event (SAE) An SAE is any adverse drug experience occurring at any dose that results in any of the following outcomes:  • Death, • A life-threatening event (at risk of death at the time of the event),  • Requires inpatient hospi[INVESTIGATOR_1081], or • A persistent or significant disability/incapacity Important medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. A distinction should be drawn between serious and severe AE’s.  A severe AE is a major event of its type.  A severe AE does not necessarily need to be considered serious.  For example, nausea that persists for several hours may be considered severe nausea, but would not be an SAE.  On the other hand, a stroke that results in only a limited degree of disability may be considered a mild stroke, but would be an SAE.  9.4.1 Relationship of Serious Adverse Events to Study Drug or Other Intervention The relationship of each SAE to the study intervention will be characterized using one of the following terms: definitely, probably, possibly, unlikely, or unrelated.  9.5 IRB/IEC Notification of Serious Adverse Events and Other Unanticipated Problems The investigator will promptly notify the IRB of all on-site unanticipated, SAE’s that are related to the research activity. Other unanticipated problems related to the research involving risk to subjects or others will also be reported promptly to the IRB. Written reports will be filed using the eIRB system and in accordance with the timeline below. External SAE’s that are both unexpected and related to the study intervention will be reported promptly after the investigator receives the report. Type of Unanticipated Problem Initial Notification  (Phone, Email, Fax) Written Report Internal (on-site) SAEs Death or Life Threatening  24 hours Within 2 calendar days Internal (on-site) SAEs All other SAEs 7 days Within 7 business days Unanticipated Problems Related to Research 7 days  Within 7 business days All other AEs N/A Brief Summary of important AEs may be reported at time of continuing review 
  Protocol No. 13-101227    
04/06/2018 V 0.16  27 9.5.1 Follow-up report If an SAE has not resolved at the time of the initial report and new information arises that changes the investigator’s assessment of the event, a follow-up report including all relevant new or reassessed information (e.g., concomitant medication, medical history) should be submitted to the IRB. The investigator is responsible for ensuring that all SAE’s are followed until either resolved or stable.  9.[ADDRESS_131392] will immediately be referred to a local hospi[INVESTIGATOR_3409].  
  Protocol No. 13-101227    
04/06/[ADDRESS_131393]. Putt, will generate a randomization schedule that will be implemented in the randomization module of the study database system. The randomization scheme will be based on equal allocation of BCAA’s to placebo and stratified based on sex. Upon confirmation of eligibility in the DMS, the randomization module will be programmed to generate a randomization number that corresponds to a unique kit number of BCAA or placebo treatment. This kit number will be used to distribute treatment. 10.1.[ADDRESS_131394] access to the information that links the kit number to the treatment arm. He/she will provide this information to the Investigational Drug Service (IDS) so that kits are prepared according to this scheme. BCAA and placebo treatment kits will appear identical. They will be labeled with the following information: 1. Kit number 2. Study name [CONTACT_114040] 3. Bottle # X of 42. 4. Subject ID # [blank line to record this number] 10.1.[ADDRESS_131395] be documented. 10.2 Data Collection and Management Procedures to assure confidentiality will be strictly observed.  All identifiable personal health information (PHI) data will be 1) kept in confidential locked files; 2) identified by [CONTACT_117789]; and 3) kept separately from identifying information used for subject tracking and follow-up contact. Identifying information will be kept in separate locked files. No identifying information will be disclosed in reports, publications, or presentations. Protection of subjects depends on the joint activities of all clinical staff as well as the database administrative team. Extensive efforts will be made to ensure that subjects’ confidentiality is maintained. Each subject will be assigned a unique study identification number and is never tracked through the study by [CONTACT_2300], medical record number, or any other personal identifier. A log of the subject names, ID numbers, and pertinent registration information (e.g., home address, telephone number, and emergency contact [CONTACT_3031]) is maintained in a separate, locked area at the clinical site. The database administrative staff will not have access to this information. Only the subject ID number and date of birth are given to the database administrative staff and registered in the study database. Any communication between the database administrative staff and investigators regarding subject 
  Protocol No. 13-101227    
04/06/[ADDRESS_131396] all personal information removed.  Study data will be entered into a web based data management system (DMS).  This DMS uses a secure connection between the client browser at the clinical site and the web server at the Penn Clinical Research Computing Unit (CRCU).  Data transmitted over this connection is authenticated by [CONTACT_117790].  Data is being gathered and stored through the CRCU because the expertise of the CRCU staff was required to construct the secure website subjects will access to complete daily assessments and to build the DMS on an Oracle platform so it can communicate in a subject-specific manner directly and securely with the Axon Sports system.  The Oracle development tools integrate seamlessly with the DMS to allow a full range of programming functionality which allow us to: 1) capture data from remote locations over the internet using secure connections, 2) incorporate data quality checks at entry and after entry using simple or complex rule sets as needed, 3) assign specific privileges for users to reflect their role and needs on the project, to provide an electronic audit trail of all data changes, 4) incorporate and enforce workflow logic where appropriate, 5) integrate with external data and software systems, and 6) provide secure and convenient access to data for authorized study personnel.  Using this platform, the DMS automatically transmits a subject’s ID number and date of birth to the Axon Sports system.  The Axon Sports system then securely sends coded data to the DMS where it is stored.  At no point is PHI except date of birth (for the purposes of computing a participant’s age) collected by [CONTACT_117791].  The Axon Sports system does not have direct access to the DMS.  All information transmitted between the Axon Sports system and the DMS is coded solely by [CONTACT_12929].   The DMS will be designed to prevent unauthorized access to trial data and to prevent data loss due to equipment failure or catastrophic events. The procedures to do so encompass user account management, user privilege assignment, data loss prevention (database backup), computer systems validation, performance monitoring, and the DMS change management. User access will be controlled by [CONTACT_117792], passwords, and role assignment. The system will meet the applicable Federal regulatory requirements and those described in the E6 Good Clinical Practice Guidelines to ensure the confidentiality of trial subjects.  CRCU data networks comprise a set of physical data networks all linked in a point-to-point configuration to form a single logical data network.  The network is protected through the use of several Juniper® firewall devices.  These devices perform as firewalls and logging devices for data network traffic, as Intrusion Detection to alarm information technology personnel to possible network attack scenarios, and as an email spam filter and eliminator. Security requirements at the computer systems’ level start with separation of duties with the system administrators.  Administrators each are assigned specific accounts that dictate what services they have access to.  All accounts are individually assigned and logged, regardless of access level.   The systems are configured to vendor specification with the published operating system releases and published patches, before connected to any data network.  Once configured, the systems operating system is imaged and TripWire® software is loaded 
  Protocol No. 13-101227    
04/06/[ADDRESS_131397] to provide business continuity, disaster recovery, and file restoration.  All hardware/system software components are covered by [CONTACT_117793] a 4-hour or less turn-around on parts and assistance. Computer system security will be enhanced for the applications through the use of the Oracle database repositories.  Users of the applications will not be allowed to log into any of the project servers directly.  All users of the project will only log into specific applications where access is controlled and limited. 10.[ADDRESS_131398] (HIPAA) on subject privacy.  The investigator and all other personnel will not use such data and records for any purpose other than conducting the study. Subjects will be assigned study numbers for entry into the protocol; this number alone will identify them. Subjects are free to refuse participation in the study and can withdraw at any time without compromising clinical care.  The investigator will obtain a data use agreement between the provider (the PI) of the data and any recipi[INVESTIGATOR_5772] (including others at CHOP) before sharing a limited dataset (PHI limited to dates and zip codes).  10.[ADDRESS_131399] has served in prior and ongoing clinical trials as endpoint adjudicator and was on the Clinical Event Committee for the pediatric EXCOR Berlin heart trial.  She is presently a member of the endpoint adjudication committee for the Thrombolysis in Pediatric Stroke trial.  The Medical Monitor will review all acute AE’s regardless of how the investigator reports the relationship between the event and the study intervention. All patient deaths will be similarly reviewed.  The study will also undergo monitoring by [CONTACT_117794]. 13-101227    
04/06/[ADDRESS_131400] safety will be monitored by [CONTACT_117795]’s on a weekly basis.  Expected adverse experiences during this study may include gastrointestinal symptoms such as dyspepsia either from the BCAA’s themselves or the [ADDRESS_131401] shown that these symptoms when related to BCAA’s are mild and transient.   An informal inquiry of athletes (both male and female) from many sports indicated that drinking [ADDRESS_131402] an alternative explanation (e.g. development of acute gastroenteritis from an identifiable source) or spontaneously resolve in less than [ADDRESS_131403]’s participation in the study.  BCAA therapy will be discontinued for any SAE related to its use.  10.4.3 Potential Benefits of Trial Participation By [CONTACT_117796].  Successful development of this compound may modify clinical protocols for treating concussion and other types of TBI.  10.4.4 Risk-Benefit Assessment Although this study involves more than minimal risk (i.e. administration of a test substance), there is the potential for benefit directly or through new knowledge.  We believe that the risk to benefit ratio is favorable and the risks are reasonable in relation to the potential benefit and new broadly applicable knowledge. 10.5 Recruitment Strategy Physicians with experience in diagnosing patients with concussion, will identify potential subjects and refer them to the study coordinator for participation in the study.  These providers typi[INVESTIGATOR_117756] a few days of their suspected concussion.  Recruitment will primarily occur through CHOP Sports Medicine, the CHOP Emergency Department, University of Pennsylvania Sports Medicine, the Hospi[INVESTIGATOR_117757] (HUP) Emergency Department, and Penn Presby[CONTACT_117797] (Presby [INVESTIGATOR_6679]).   
  Protocol No. 13-101227    
04/06/[ADDRESS_131404]’s permission, the provider will contact [CONTACT_117798]’s contact [CONTACT_3031].  Physicians in the CHOP Emergency Department will identify potential subjects for this study. Once a patient has been diagnosed by [CONTACT_117799] a concussion, a referral will be made to the study coordinator and a HIT-HEADS Study informational sheet will be provided to the patient. The study coordinator will arrange to complete the remainder of the screening process in a designated office or clinical exam after discharge from the ED.  For Penn Sports medicine, providers will identify potential subjects and with the subject’s permission, the provider will contact [CONTACT_117798]’s contact [CONTACT_3031]. Providers in the HUP ED, and Presby [CONTACT_117800].  They will provide a HIT-HEADS informational sheet to a patient once they have been diagnosed with a concussion.  The patient will then contact [CONTACT_117801].  Providers from these entities will not collect or transmit patient information to the study coordinator.  Once the study coordinator has made contact [CONTACT_4490] a potential subject, he or she will make arrangements with the potential subject to complete the remainder of the screening process in a designated office or clinical exam room. Subjects may self-refer to the study. Informational flyers will also be displayed and distributed in University of Pennsylvania campus, including student gathering places, locker rooms, training facilities and sports medicine clinics to inform subjects about the study.  Patients greater than [ADDRESS_131405] in the mail.  Those patients that selected to receive CHOP emails will also receive an email from the PI. Marianne Chilutti, Department of Biomedical and Health Informatics (DBHi) will query the CHOP EPIC system for patients, ages [ADDRESS_131406] been diagnosed with a concussion (ICD-9-CM codes 850, 850.0, 850.1, 850.10, 850.11, 850.5, 850.9) or made a call to the triage nurse after business hours with the complaint of a concussion .  The search will be limited by [CONTACT_117802]. The report will be run daily and the results emailed to the study team.  A medical record review using the EPIC database will be conducted by [CONTACT_117803].  Specifically, the medical record will be searched for the manner and time of the concussion to determine which patients are eligible for contact.  A study team member will then contact [CONTACT_117804]. High school administrative and athletic personnel from the school districts in the greater Philadelphia area will be given information about the study through informational fliers. Additional information about how to refer concussed players to the study will be communicated to nurses, coaches and team medical staff if the school is interested in participation. As with recruitment from other domains, potential subjects will be required to 
  Protocol No. 13-101227    
04/06/[ADDRESS_131407] the study coordinator directly and the diagnosis of concussion will be confirmed by a physician prior to enrollment. Upon approval from high school administrative personnel, a member of the study team will attend back to school night to distribute approved study materials including flyers and business cards.  Approval will be documented in the form of a letter/email of confirmation from a high school administrator. The UNTOLD Foundation will display the approved flyer on the organization’s homepage, http://www.theuntoldfoundation.org/. The Recruitment Enhancement Core (REC) may provide assistance with recruitment plan development and may assist in identifying and contact[CONTACT_117805], the CHOP Recruitment Registry, social media and internal communication resources. The REC also may engage community partners and facilitate outreach on behalf of the Research Institute and this CHOP research study. 10.6 Informed Consent/Assent and HIPAA Authorization Informed consent is an ongoing process that takes place between the investigator/study staff and study participants. The PI [INVESTIGATOR_7516] (physician co-investigators) will obtain informed consent for this research study.  The consent process will occur in a designated office or clinical exam room at CHOP or Penn. It is the responsibility of the PI [INVESTIGATOR_117758].  The consent will include use of the information obtained during the clinical battery before enrollment and all data obtained after enrollment.  Subjects may take any additional time needed to review the consent document, however, initiating the trial may not begin more than 72 hours after the time of injury.  Adult subjects age ≥[ADDRESS_131408] is a <[ADDRESS_131409] assent.  10.7 Payment to Subjects/Families Subjects will receive a possible total of $[ADDRESS_131410] and money added throughout the study.  Subjects will receive $[ADDRESS_131411] at the time of visit 1.  Each day that they input all required study data will add $1, with a bonus of $2 each time 3 days in a row are met and $5 each time 7 days in a row are met, for a possible total of $50 if all 21 days of data are entered completely.  $10 will be added for each in-person research visit that they attend (possible total of $30 for 3 visits)..  10.7.1 Reimbursement for travel, parking and meals Subjects who park at a CHOP facility that requires paid parking for any of their 4 research visits will receive parking vouchers.   
  Protocol No. 13-101227    
04/06/2018 V 0.16  34 11 PUBLICATION The principal investigator [INVESTIGATOR_6254]-investigators will prepare the data for publication.     
  Protocol No. 13-101227    
04/06/[ADDRESS_131412] KB. Pediatric Providers' Self-Reported Knowledge, Practices, and Attitudes About Concussion. Pediatrics. 2012; 6: 1120-1125. 2.      Cole JT, Mitala CM, Kundu S, et al. Dietary branched chain amino acids ameliorate injury-induced cognitive impairment. Proc Natl Acad Sci U S A 2010;107:366-371. 3. Fernstrom JD. Branched-chain amino acids and brain function. J Nutr 2005;135:1539S-1546S. 4. Jeter CB, Hergenroeder GW, Ward NH, 3rd, Moore AN, Dash PK. Human mild traumatic brain injury decreases circulating branched-chain amino acids and their metabolite levels. Journal of neurotrauma 2013;30:671-679. 5. Aquilani R, Viglio S, Iadarola P, et al. Peripheral plasma amino acid abnormalities in rehabilitation patients with severe brain injury. Archives of physical medicine and rehabilitation 2000;81:176-181. 6. Aquilani R, Iadarola P, Boschi F, Pi[INVESTIGATOR_117759] C, Arcidiaco P, Contardi A. Reduced plasma levels of tyrosine, precursor of brain catecholamines, and of essential amino acids in patients with severe traumatic brain injury after rehabilitation. Archives of physical medicine and rehabilitation 2003;84:1258-1265. 7. Aquilani R, Iadarola P, Contardi A, et al. Branched-chain amino acids enhance the cognitive recovery of patients with severe traumatic brain injury. Arch Phys Med Rehabil 2005;86:1729-1735. 8. Aquilani R, Boselli M, Boschi F, et al. Branched-chain amino acids may improve recovery from a vegetative or minimally conscious state in patients with traumatic brain injury: a pi[INVESTIGATOR_799]. Archives of physical medicine and rehabilitation 2008;89:1642-1647. 9. Mager DR, Wykes LJ, Ball RO, Pencharz PB. Branched-chain amino acid requirements in school-aged children determined by [CONTACT_117806] (IAAO). The Journal of nutrition 2003;133:3540-3545. 10. Mager DR, Wykes LJ, Roberts EA, Ball RO, Pencharz PB. Branched-chain amino acid needs in children with mild-to-moderate chronic cholestatic liver disease. J Nutr 2006;136:133-139. 11. Berry HK, Bofinger MK, Hunt MM, Phillips PJ, Guilfoile MB. Reduction of cerebrospi[INVESTIGATOR_117760], isoleucine, and leucine. Pediatric research 1982;16:751-755. 12. Berry HK, Brunner RL, Hunt MM, White PP. Valine, isoleucine, and leucine. A new treatment for phenylketonuria. Am J Dis Child 1990;144:539-543. 13. Jordan MK, Brunner RL, Hunt MM, Berry HK. Preliminary support for the oral administration of valine, isoleucine and leucine for phenylketonuria. Dev Med Child Neurol 1985;27:33-39. 14. Chin SE, Shepherd RW, Thomas BJ, et al. Nutritional support in children with end-stage liver disease: a randomized crossover trial of a branched-chain amino acid supplement. The American journal of clinical nutrition 1992;56:158-163. 15. Chin SE, Shepherd RW, Cleghorn GJ, et al. Pre-operative nutritional support in children with end-stage liver disease accepted for liver transplantation: an approach to management. Journal of gastroenterology and hepatology 1990;5:566-572. 16. Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry 2004;65:92-96. 17. Evangeliou A, Spi[INVESTIGATOR_117761] M, Doulioglou V, et al. Branched chain amino acids as adjunctive therapy to ketogenic diet in epi[INVESTIGATOR_002]: pi[INVESTIGATOR_92044]. Journal of child neurology 2009;24:1268-1272. 18. Scarna A, Gijsman HJ, McTavish SF, Harmer CJ, Cowen PJ, Goodwin GM. Effects of a branched-chain amino acid drink in mania. Br J Psychiatry 2003;182:210-213. 19. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 2003;160:1117-1124. 20. Mori M, Adachi Y, Mori N, et al. Double-blind crossover study of branched-chain amino acid therapy in patients with spi[INVESTIGATOR_117746]. J Neurol Sci 2002;195:149-152. 21. Cangiano C, Laviano A, Meguid MM, et al. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst 1996;88:550-552. 
  Protocol No. 13-101227    
04/06/[ADDRESS_131413] Rev 2003:CD001939. 23. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005;3:705-713. 24. Kuroda H, Ushio A, Miyamoto Y, et al. Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. J Gastroenterol Hepatol 2010;25:1550-1555. 25. Gijsman HJ, Scarna A, Harmer CJ, et al. A dose-finding study on the effects of branch chain amino acids on surrogate markers of brain dopamine function. Psychopharmacology (Berl) 2002;160:192-197. 26. Tsubuku S, Hatayama K, Katsumata T, et al. Thirteen-week oral toxicity study of branched-chain amino acids in rats. Int J Toxicol 2004;23:119-126. 27. Collie A, Makdissi M, Maruff P, Bennell K, McCrory P. Cognition in the days following concussion: comparison of symptomatic versus asymptomatic athletes. J Neurol Neurosurg Psychiatry 2006;77:241-245. 28. Maruff P, Thomas E, Cysique L, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 2009;24:165-178. 29. Straume-Naesheim TM, Andersen TE, IM KH, McIntosh AS, Dvorak J, Bahr R. Do minor head impacts in soccer cause concussive injury? A prospective case-control study. Neurosurgery 2009;64:719-725; discussion 725. 30. Makdissi M, Darby D, Maruff P, Ugoni A, Brukner P, McCrory PR. Natural history of concussion in sport: markers of severity and implications for management. Am J Sports Med 2010;38:464-471. 31. Moriarity J, Collie A, Olson D, et al. A prospective controlled study of cognitive function during an amateur boxing tournament. Neurology 2004;62:1497-1502. 32. Collie A, Maruff P, Makdissi M, McCrory P, McStephen M, Darby [CONTACT_24226]. CogSport: Reliability and correlation with conventional cognitive tests used in post-concussion medical examinations. Clinical Journal of Sport Medicine 2003;13:28-32. 33. Falleti MG, Maruff P, Collie A, Darby [CONTACT_24226]. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol 2006;28:1095-1112. 34. Falleti MG, Maruff P, Collie A, Darby [CONTACT_24226], McStephen M. Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05%. J Sleep Res 2003;12:265-274. 35. Fredrickson J, Maruff P, Woodward M, et al. Evaluation of the usability of a brief computerized cognitive screening test in older people for epi[INVESTIGATOR_9037]. Neuroepi[INVESTIGATOR_623] 2010;34:65-75. 36. Maruff P, Falleti MG, Collie A, Darby D, McStephen M. Fatigue-related impairment in the speed, accuracy and variability of psychomotor performance: comparison with blood alcohol levels. J Sleep Res 2005;14:21-27. 37. Mollica CM, Maruff P, Collie A, Vance A. Repeated assessment of cognition in children and the measurement of performance change. Neuropsychol Dev Cogn C Child Neuropsychol 2005;11:303-310. 38. McKay J, Betts J, Maruff P, Anderson V. An examination of developmental trajectories for attention skills in children. The Australian Educational and Developmental Psychologist 2011;27:76-89. 39. Betts J, McKay J, Maruff P, Anderson V. The development of sustained attention in children: the effect of age and task load. Child Neuropsychol 2006;12:205-221. 40. Straume-Naesheim TM, Andersen TE, Bahr R. Reproducibility of computer based neuropsychological testing among Norwegian elite football players. Br J Sports Med 2005;[ADDRESS_131414] 1:i64-69. 41. Makdissi M, Collie A, Maruff P, et al. Computerised cognitive assessment of concussed Australian Rules footballers. Br J Sports Med 2001;35:354-360. 42. Makdissi M, Collie A, Maruff P, McCrory P, Brukner P, Bennell K. Does baseline neuropsychological test performance change from year to year in non-injured athletes?  Second International Conference on Concussion in Sport; 2004; Prague. 
  Protocol No. 13-101227    
04/06/[ADDRESS_131415]-concussion cognitive function in symptomatic and asymptomatic athletes.  Second International Conference on Concussion in Sport; 2004; Prague. 44. Pi[INVESTIGATOR_117762], Motl RW, Guskiewicz KM, McCrea M, Ferrara MS. Structural validity of a self-report concussion-related symptom scale. Med Sci Sports Exerc 2006;38:27-32. 45. Cohen HS, Kimball KT. Usefulness of some current balance tests for identifying individuals with disequilibrium due to vestibular impairments. J Vestib Res 2008;18:295-303. 45. McCrory P, Meeuwisse WH, Aubry M, et al. Consensus statement on concussion in sport: the 5th International Conference on Concussion in Sport held in Berlin, October 2016. British Journal of Sports Medicine 2017;51(11):found at http://bjsm.bmj.com/content/51/11/838. Last accessed December 7, 2017. 46. Pauler DK, Laird NM. A mixture model for longitudinal data with application to assessment of noncompliance. Biometrics 2000;56:464-472. 47. Hall CB, Lipton RB, Sliwinski M, Stewart WF. A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease. Stat Med 2000;19:1555-1566. 48. Rodewald LE, Pi[INVESTIGATOR_19276]. Compliance with antibiotic therapy: a comparison of deuterium oxide tracer, urine bioassay, bottle weights, and parental reports. The Journal of pediatrics 1993;123:143-147. 49. Rodewald LE, Maiman LA, Foye HR, Borch RF, Forbes GB. Deuterium oxide as a tracer for measurement of compliance in pediatric clinical drug trials. The Journal of pediatrics 1989;114:885-891. 50. Fusch C, Moeller H. Measurement of D2O concentrations at tracer levels in small samples obtained from paediatric patients. J Clin Chem Clin Biochem 1988;26:715-721. 51. Cromer JA, Schembri AJ, Harel BT, Maruff P. The nature and rate of cognitive maturation from late childhood to adulthood. Front Psychol. 2015;6:1-12.  52.    Petry NM, Barry D, Pescatello L, White WB. A low-cost reinforcement procedure improves short-term weight loss outcomes. The American Journal of Medicine. 2011; 124: 1082-1085. 53.    Hackenberg, Timothy D. Token reinforcement: A review and analysis. Journal of the experimental analysis of behavior. 2009; 91: 257-286. 54.    Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, Loewenstein G. Financial incentive—based approaches for weight loss: a randomized trial. Jama. 2008; 300: 2631-2637.  55.   Reese PP, Bloom RD, Trofe-Clark J, Mussell A, Leidy D, Levsky S, Zhu J. Automated reminders and physician notification to promote immunosuppression adherence among kidney transplant receipents: a randomized trial. American Journal of Kidney Diseases. 2017; 69: 400-409. 56.   Haff N, Patel MS, Lim R, Zhu J, Troxel AB, Asch DA, Volpp KG. The role of behavioral economic incentive design and demographic characteristics in financial incentive-based approaches to changing health behaviors: a meta-analysis. American Journal of Health Promotion. 2015; 29: 314-323.   
  Protocol No. 13-101227    
04/06/2018 V 0.16  38 13 APPENDICES 13.1 APPENDIX 1: Clinical Symptom Checklist 
 
   

  Protocol No. 13-101227    
04/06/2018 V 0.16  39 13.2 APPENDIX 2: Physical and Cognitive Activity Assessments Please indicate your level of cognitive activity in the past day [insert date]: 1. Cognitive Activity: q0 Complete cognitive rest  q1 Not attending school/work, but doing light cognitive activity, (e.g. watching TV, pleasure reading or using the Internet)  q2 Not attending school/work, but doing moderate cognitive activity, (e.g. homework, academic reading, school/work-related computer use)  q3 Attending school/work with decreased workload (e.g. not taking exams, taking a reduced number of courses)  q4 Full unrestricted participation in school/work including all exams, assignments, and homework  Please indicate your level of physical activity in the past day [insert date]: 2. Physical Activity: q0 Complete physical rest  q1 Light aerobic activity (e.g. walking, swimming or stationary cycling)  q2 Moderate non-contact [CONTACT_14759] (e.g. running, skating drills in hockey, running drills in soccer or football)  q3 Complex activity or drills involving partial participation (e.g. passing or shooting drills in sports, partial participation in gym class or exercise classes)  q4 Complex activity or drills with full participation (e.g. full contact [CONTACT_14603], normal training activities, full participation in gym class or exercise classes)  q5 Normal activity level without limitation, including normal game or scrimmage play     
  Protocol No. 13-101227    
04/06/2018 V 0.16  40 13.3 APPENDIX 3: Sleep Assessment  
    

  Protocol No. 13-101227    
04/06/2018 V 0.16  41 13.4 APPENDIX 4: Drug accountability assessment   
